Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism

Kidney International

Volumn 84, Issue 6, 2013, Pages 1189-1197

  You, Hanning ^a   Gao, Ting ^a   Cooper, Timothy K ^a   Morris, Sidney M ^b   Awad, Alaa S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

albuminuria; diabetic nephropathy; nitric oxide

Indexed keywords

ARGINASE; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRONECTIN; NITROGEN; TUMOR NECROSIS FACTOR ALPHA; UREA;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HISTOPATHOLOGY; KIDNEY PARENCHYMA; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UREA NITROGEN BLOOD LEVEL; WILD TYPE;

ALBUMINURIA; ANIMALS; ARGINASE; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; BORONIC ACIDS; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; FIBRONECTINS; INFUSIONS, SUBCUTANEOUS; KIDNEY; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; ORNITHINE; OXIDATIVE STRESS; STREPTOZOCIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888646474     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.215     Document Type: Article

References (48)

1. Boyle JP, Thompson TJ, Gregg EW et al. Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 8: 29.
2. Creager MA, Luscher TF, Cosentino F et al. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527-1532.
3. Goligorsky MS, Chen J, Brodsky S. Workshop: Endothelial cell dysfunction leading to diabetic nephropathy: Focus on nitric oxide. Hypertension 2001; 37: 744-748.
4. Xia Y, Dawson VL, Dawson TM et al. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 1996; 93: 6770-6774.
5. Brodsky SV, Gao S, Li H et al. Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am J Physiol Heart Circ Physiol 2002; 283: H2130-H2139.
6. Wang CH, Li F, Hiller S et al. A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy. Proc Natl Acad Sci USA 2011; 108: 2070-2075.
7. Zhao HJ, Wang S, Cheng H et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006; 17: 2664-2669.
8. Balakumar P, Chakkarwar VA, Krishan P et al. Vascular endothelial dysfunction: A tug of war in diabetic nephropathy? Biomed Pharmacother 2009; 63: 171-179.
9. Morris SM Jr. Recent advances in arginine metabolism: Roles and regulation of the arginases. Br J Pharmacol 2009; 157: 922-930.
10. Zhang C, Hein TW, Wang W et al. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 2001; 15: 1264-1266.
11. Berkowitz DE, White R, Li D et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003; 108: 2000-2006.
12. Lim HK, Ryoo S, Benjo A et al. Mitochondrial arginase II constrains endothelial NOS-3 activity. Am J Physiol Heart Circ Physiol 2007; 293: H3317-H3324.
13. Levillain O, Balvay S, Peyrol S. Localization and differential expression of arginase II in the kidney of male and female mice. Pflugers Arch 2005; 449: 491-503.
14. Levillain O, Balvay S, Peyrol S. Mitochondrial expression of arginase II in male and female rat inner medullary collecting ducts. J Histochem Cytochem 2005; 53: 533-541.
15. Morris SM Jr., Bhamidipati D, Kepka-Lenhart D. Human type II arginase: Sequence analysis and tissue-specific expression. Gene 1997; 193: 157-161.
16. Morris SM Jr., Gao T, Cooper TK et al. Arginase-2 mediates diabetic renal injury. Diabetes 2011; 60: 3015-3022.
17. Bagnost T, Berthelot A, Bouhaddi M et al. Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-Arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. J Hypertens 2008; 26: 1110-1118.
18. Ckless K, Lampert A, Reiss J et al. Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration. J Immunol 2008; 181: 4255-4264.
19. Maarsingh H, Zuidhof AB, Bos IS et al. Arginase inhibition protects against allergen-induced airway obstruction, hyperresponsiveness, and inflammation. Am J Respir Crit Care Med 2008; 178: 565-573.
20. Reid KM, Tsung A, Kaizu T et al. Liver I/R injury is improved by the arginase inhibitor, N(omega)-hydroxy-nor-L-Arginine (nor-NOHA). Am J Physiol Gastrointest Liver Physiol 2007; 292: G512-G517.
21. Jeyabalan G, Klune JR, Nakao A et al. Arginase blockade protects against hepatic damage in warm ischemia-reperfusion. Nitric Oxide 2008; 19: 29-35.
22. Xu L, Hilliard B, Carmody RJ et al. Arginase and autoimmune inflammation in the central nervous system. Immunology 2003; 110: 141-148.
23. Bivalacqua TJ, Burnett AL, Hellstrom WJ et al. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: Influence of in vivo gene therapy of anti-Arginase. Am J Physiol Heart Circ Physiol 2007; 292: H1340-H1351.
24. Nakagawa T, Tanabe K, Croker BP et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol 2010; 7: 36-44.
25. Wu G, Morris SM Jr. Arginine metabolism: Nitric oxide and beyond. Biochem J 1998; 336(Pt 1): 1-17.
26. Morris SM Jr., Kepka-Lenhart D, Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol 1998; 275: E740-E747.
27. Awad AS, Kinsey GR, Khutsishvili K et al. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am J Physiol Renal Physiol 2011; 301: F1358-F1366.
28. Awad AS, Huang L, Ye H et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F828-F837.
29. Benigni A, Zoja C, Corna D et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14: 1816-1824.
30. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637.
31. Tang WW, Qi M, Warren JS. Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int 1996; 50: 665-671.
32. Wada T, Furuichi K, Sakai N et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000; 58: 1492-1499.
33. Giunti S, Barutta F, Perin PC et al. Targeting the MCP-1/CCR2 system in diabetic kidney disease. Curr Vasc Pharmacol 8: 849-860.
34. Tipping PG, Leong TW, Holdsworth SR. Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. Lab Invest 1991; 65: 272-279.
35. Tipping PG, Lowe MG, Holdsworth SR. Glomerular interleukin 1 production is dependent on macrophage infiltration in anti-GBM glomerulonephritis. Kidney Int 1991; 39: 103-110.
36. Ming XF, Rajapakse AG, Yepuri G et al. Arginase II promotes macrophage inflammatory responses through mitochondrial reactive oxygen species, contributing to insulin resistance and atherogenesis. J Am Heart Assoc 2012; 1: E000992.
37. Awad AS, Webb RL, Carey RM et al. Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade. J Hypertens 2004; 22: 1571-1577.
38. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium- vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-438.
39. Du XL, Edelstein D, Dimmeler S et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108: 1341-1348.
40. Hink U, Li H, Mollnau H et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88: E14-E22.
41. Faria AM, Papadimitriou A, Silva KC et al. Uncoupling endothelial nitric oxide synthase is ameliorated by green tea in experimental diabetes by re-establishing tetrahydrobiopterin levels. Diabetes 2012; 61: 1838-1847.
42. Yagihashi N, Nishida N, Seo HG et al. Expression of nitric oxide synthase in macula densa in streptozotocin diabetic rats. Diabetologia 1996; 39: 793-799.
43. Brodsky SV, Morrishow AM, Dharia N et al. Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol 2001; 280: F480-F486.
44. Wehbi GJ, Zimpelmann J, Carey RM et al. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol 2001; 280: F254-F265.
45. Shi W, Wang X, Shih DM et al. Paradoxical reduction of fatty streak formation in mice lacking endothelial nitric oxide synthase. Circulation 2002; 105: 2078-2082.
46. Shi O, Morris SM Jr., Zoghbi H et al. Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol 2001; 21: 811-813.
47. Lapenna D, Ciofani G, Pierdomenico SD et al. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic Biol Med 2001; 31: 331-335.
48. Kepka-Lenhart D, Ash DE, Morris SM. Determination of mammalian arginase activity. Methods Enzymol 2008; 440: 221-230.